Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema. It also develops ARP-1536, a humanized monoclonal antibody that is in late stage preclinical development for the treatment of wet age-related macular degeneration; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a Phase 1a clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone513-985-1920
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Aerpio Pharmaceuticals (OTCMKTS:ARPO) Frequently Asked Questions
What is Aerpio Pharmaceuticals' stock symbol?
Aerpio Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ARPO."
How were Aerpio Pharmaceuticals' earnings last quarter?
Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) announced its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.21) EPS for the quarter, beating the Zacks' consensus estimate of ($0.22) by $0.01. View Aerpio Pharmaceuticals' Earnings History.
What price target have analysts set for ARPO?
5 brokers have issued twelve-month price objectives for Aerpio Pharmaceuticals' stock. Their predictions range from $8.00 to $10.00. On average, they expect Aerpio Pharmaceuticals' share price to reach $9.25 in the next twelve months. This suggests a possible upside of 725.9% from the stock's current price. View Analyst Price Targets for Aerpio Pharmaceuticals.
What is the consensus analysts' recommendation for Aerpio Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerpio Pharmaceuticals in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aerpio Pharmaceuticals.
What are Wall Street analysts saying about Aerpio Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aerpio Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "As we roll forward the DCF analysis, our estimated market value of the firm has increased to $400M from $395M, which includes a discounted cash flow-based asset value for AKB-9778 and AKB-4924 (now GB004), using a 15% discount rate and 2% terminal growth rate, and probabilities of success at 30% and 10%, respectively." (3/6/2019)
- 2. According to Zacks Investment Research, "Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. It focuses on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The Company' product candidates include AKB?9778, ARP1536 and AKB-4924 which are in clinical stage. Aerpio Pharmaceuticals Inc. is based in Cincinnati, United States. " (10/16/2018)
Has Aerpio Pharmaceuticals been receiving favorable news coverage?
Press coverage about ARPO stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aerpio Pharmaceuticals earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term.
Who are some of Aerpio Pharmaceuticals' key competitors?
Some companies that are related to Aerpio Pharmaceuticals include resTORbio (TORC), Cue Biopharma (CUE), Ocular Therapeutix (OCUL), Nature's Sunshine Products (NATR), Aquestive Therapeutics (AQST), Axovant Sciences (AXON), Neos Therapeutics (NEOS), ProMetic Life Sciences (PFSCF), Bellicum Pharmaceuticals (BLCM), Humanigen (HGEN), Northwest Biotherapeutics (NWBO), Spring Bank Pharmaceuticals (SBPH), Trevena (TRVN), CytoDyn (CYDY) and PhaseBio Pharmaceuticals (PHAS).
What other stocks do shareholders of Aerpio Pharmaceuticals own?
Who are Aerpio Pharmaceuticals' key executives?
Aerpio Pharmaceuticals' management team includes the folowing people:
- Dr. Joseph H. Gardner, Founder, Pres & Director (Age 62)
- Mr. Kevin G. Peters M.D., Ph.D., Chief Scientific Officer & Sr. VP (Age 61)
- Dr. Stephen Pakola M.D., Chief Medical Officer (Age 49)
- Dr. Stephen J. Hoffman, CEO & Director (Age 64)
- Mr. Michael W. Rogers, Chief Financial Officer (Age 58)
Who are Aerpio Pharmaceuticals' major shareholders?
Aerpio Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Citigroup Inc. (0.60%), CVI Holdings LLC (0.41%), HarbourVest Partners LLC (0.36%), Jane Street Group LLC (0.20%), Bank of New York Mellon Corp (0.05%) and Acadian Asset Management LLC (0.04%). Company insiders that own Aerpio Pharmaceuticals stock include Bioventures Ltd Novartis, Muneer A Satter and Stephen J Hoffman. View Institutional Ownership Trends for Aerpio Pharmaceuticals.
Which institutional investors are selling Aerpio Pharmaceuticals stock?
Which institutional investors are buying Aerpio Pharmaceuticals stock?
ARPO stock was bought by a variety of institutional investors in the last quarter, including Citigroup Inc., HarbourVest Partners LLC, Jane Street Group LLC, Bank of New York Mellon Corp and Acadian Asset Management LLC. Company insiders that have bought Aerpio Pharmaceuticals stock in the last two years include Muneer A Satter and Stephen J Hoffman. View Insider Buying and Selling for Aerpio Pharmaceuticals.
How do I buy shares of Aerpio Pharmaceuticals?
Shares of ARPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aerpio Pharmaceuticals' stock price today?
One share of ARPO stock can currently be purchased for approximately $1.12.
How big of a company is Aerpio Pharmaceuticals?
Aerpio Pharmaceuticals has a market capitalization of $45.46 million.
What is Aerpio Pharmaceuticals' official website?
How can I contact Aerpio Pharmaceuticals?
Aerpio Pharmaceuticals' mailing address is 9987 CARVER ROAD, CINCINNATI OH, 45242. The company can be reached via phone at 513-985-1920 or via email at [email protected]
MarketBeat Community Rating for Aerpio Pharmaceuticals (OTCMKTS ARPO)
MarketBeat's community ratings are surveys of what our community members think about Aerpio Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
